Safety Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women (NCT02215434) | Clinical Trial Compass
CompletedPhase 2
Safety Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women
Brazil60 participantsStarted 2009-09
Plain-language summary
Female sexual dysfunction (FSD) is an established side effect of Selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitors (SNRIs), causing symptoms such as loss of libido, arousal difficulties, or delayed orgasm or anorgasmia.
Efficacy of testosterone therapy for the treatment of hypoactive sexual desire disorder (HSDD) in women has been demonstrated in studies including naturally and surgically menopausal women, either alone or in combination with estrogen, with or without progestin therapy.
Who can participate
Age range18 Years – 89 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* a body mass index between 18 and 35 kg/m2
* diminished libido complaints
* no evidence of severe clinical depression
* participants in good health based on history and physical examination.
Exclusion Criteria:
* a past history of neurological disorder
* recent psychiatric or systemic illness
* use of psychoactive medications
* alcohol excess consumption or any other drug abuse.
* women who had under gone treatment for cardiovascular disease, genital bleeding, acne, depression, dyspareunia or those who had received oral androgen therapy in the previous 3 months were excluded
* in addition women taking medications known to interfere with sex steroid metabolism were also excluded.